Anxiety Disorders
Anxiety disorders, affecting around 300 million people globally, are among the most prevalent mental health conditions. Emerging clinical research suggests that various psychedelics, including psilocybin, MDMA, and LSD, hold potential for alleviating anxiety symptoms through innovative therapeutic approaches.
What is Anxiety Disorders?
Anxiety is characterised by feelings of tension and excessive worry, often manifesting in symptoms that severely interfere with daily life and functioning. Common types of anxiety disorders include Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Obsessive-Compulsive Disorder (OCD), and Post-Traumatic Stress Disorder (PTSD). These conditions can coexist with depression, further complicating treatment options.
The DSM-V outlines anxiety disorders as conditions where individuals experience excessive anxiety and worry about varied topics for prolonged periods, leading to distressing symptoms such as restlessness, irritability, and sleep disturbances. With over 284 million individuals globally experiencing anxiety, the economic and personal burden is considerable.
Current Treatments
Standard treatment for anxiety disorders typically involves a combination of pharmacotherapy, including SSRIs and SNRIs, alongside psychotherapy. In cases of treatment-resistant anxiety, benzodiazepines and other anxiolytics are also employed; however, a significant proportion of patients remain unresponsive to these conventional therapies.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Anxiety Disorders.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Supported by multiple clinical trials indicating significant reductions in anxiety symptoms. | Large | Moderate | Consistent |
| MDMA Demonstrated efficacy in managing anxiety associated with PTSD and end-of-life distress. | Large | Moderate | Consistent |
| Ketamine Rapid anxiolytic effects observed in controlled trials, though effects are transient compared to classic psychedelics. | Medium | Moderate | Consistent |
| LSD Early results indicate potential efficacy, but more robust trials are needed. | Medium | Low | Inconsistent |
| Ayahuasca Limited research specifically addressing anxiety, though some anecdotal support exists. | Small | Very Low | Inconsistent |
Psilocybin and Anxiety Disorders
Psilocybin acts primarily as a 5HT-2A receptor agonist, promoting serotonin release in the brain. This activation is linked to reductions in negative emotional responses and alterations in entrenched thought patterns associated with anxiety, contributing to an improved sense of well-being and lower anxiety levels after therapy.
MDMA and Anxiety Disorders
MDMA promotes the release of serotonin, dopamine, and norepinephrine, enhancing mood and emotional openness. It is believed to reduce anxiety through its effects on the amygdala, allowing individuals to confront distressing feelings in a therapeutic context, evidenced by significant reductions in anxiety scores in clinical trials.
Ketamine and Anxiety Disorders
Ketamine serves as an NMDA receptor antagonist, leading to increased brain-derived neurotrophic factor (BDNF) secretion, which enhances synaptic plasticity. Its rapid onset of action results in swift alleviation of anxiety symptoms, particularly beneficial for patients with treatment-resistant anxiety disorders.
LSD and Anxiety Disorders
LSD functions through agonism at serotonin receptors, similar to psilocybin, and is thought to facilitate emotional processing and reduce anxiety through alterations in neural circuitry associated with the default mode network, ultimately contextualising fear and anxiety-provoking stimuli.
Key Insights
- 1
Anxiety disorders represent the most prevalent mental health conditions, contributing to 3.4% of years lived with disability globally.
- 2
Psychedelics like psilocybin and MDMA demonstrate promise in alleviating end-of-life anxiety, showing sustained improvement in clinical trials.
- 3
Ketamine has been shown to provide rapid relief for anxiety symptoms in refractory cases, with significant efficacy observed soon after administration.
- 4
Clinical trials involving psychedelics are expanding rapidly, with organisations such as MAPS and various biotech companies leading the charge in research and development.
- 5
The intersection of anxiety and depression highlights the need for innovative treatments, with ongoing studies indicating that psychedelics can address dual diagnoses effectively.
Industrial Landscape
Key players in the field include MindMed, which is developing LSD treatments for GAD in collaboration with the University of Basel, and Cybin, which is working on their proprietary CYB004 molecule targeting anxiety disorders. Non-profits like MAPS are significantly contributing to the research landscape for psychedelic-based therapies.
Quick Indicators
\"Ongoing clinical evaluations are investigating Anxiety Disorders as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Anxiety Disorders.